The Genetic Inactivation of Inducible Nitric Oxide Synthase (iNOS) Intensifies Fibrosis and Oxidative Stress in the Penile Corpora Cavernosa in Type 1 Diabetes

Journal of Sexual Medicine

Volumn 7, Issue 9, 2010, Pages 3033-3044

  Ferrini, Monica G ^a,b   Rivera, Steve ^c   Moon, Joanne ^a   Vernet, Dolores ^a,c   Rajfer, Jacob ^b,c   Gonzalez Cadavid, Nestor F ^a,b,c  

^a CHARLES R DREW UNIVERSITY OF MEDICINE AND SCIENCE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

Apoptosis; Collagen; Erectile dysfunction; Nitric oxide; Penis; Smooth muscle

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN; CYCLINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INSULIN; TRANSFORMING GROWTH FACTOR BETA1; XANTHINE OXIDASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DIVISION; CONTROLLED STUDY; CORPUS CAVERNOSUM; DIABETIC NEUROPATHY; GENE INACTIVATION; GLUCOSURIA; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PENILE FIBROSIS; PRIORITY JOURNAL; PROTEINURIA; SMOOTH MUSCLE;

EID: 77956290082     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.01884.x     Document Type: Article

References (61)

1. Ferrini MG, Kovanecz I, Sanchez S, Vernet D, Umeh C, Rajfer J, Gonzalez-Cadavid NF. Fibrosis and loss of smooth muscle in the corpora cavernosa precede corporal veno-occlusive dysfunction (CVOD) induced by experimental cavernosal nerve damage in the rat. J Sex Med 2009, 6:415-28.
2. Kovanecz I, Rambhatla A, Ferrini MG, Vernet D, Sanchez S, Rajfer J, Gonzalez-Cadavid NF. Chronic daily tadalafil prevents the corporal fibrosis and veno-occlusive dysfunction (CVOD) that occurs following cavernosal nerve resection in the rat. BJU Int 2008, 101:203-10.
3. Kovanecz I, Rambhatla A, Ferrini MG, Vernet D, Sanchez S, Rajfer J, Gonzalez-Cadavid NF. Long term sildenafil treatment ameliorates corporal veno-occlusive dysfunction (CVOD) induced by cavernosal nerve resection in rats. Int J Impot Res 2007, 100:867-74.
4. Ferrini MG, Davila H, Kovanecz I, Sanchez S, Gonzalez-Cadavid NF Rajfer J. Long-term continuous treatment with vardenafil prevents fibrosis and preserves smooth muscle content in the rat corpora cavernosa after bilateral cavernosal nerve transection. Urology 2006, 68:429-35.
5. Ferrini MG, Kovanecz I, Sanchez S, Vernet D, Davila HH, Rajfer J, Gonzalez-Cadavid NF. Long-term continuous treatment with sildenafil ameliorates aging-related erectile dysfunction and the underlying corporal fibrosis. Biol Reprod 2007, 76:915-23.
6. Kovanecz I, Ferrini MG, Davila HH, Rajfer J, Gonzalez-Cadavid NF. Pioglitazone ameliorates penile corpora veno-occlusive dysfunction (CVOD) in the aged rat. BJU Int 2007, 100:867-74.
7. Kovanecz I, Ferrini MG, Vernet D, Nolazco G, Rajfer J, Gonzalez-Cadavid NF. Pioglitazone prevents corporal veno-occlusive dysfunction (CVOD) in a rat model of type 2 diabetes melittus. BJU Int 2006, 98:116-24.
8. Iacono F, Giannella R, Somma P, Manno G, Fusco F, Mirone V. Histological alterations in cavernous tissue after radical prostatectomy. J Urol 2005, 173:1673-86.
9. McCullough A. Penile change following radical prostatectomy: Size, smooth muscle atrophy, and curve. Curr Urol Rep 2008, 9:492-9.
10. Schwartz EJ, Wong P, Graydon RJ. Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy. J Urol 2004, 171:771-4.
11. Blute M, Hakimian P, Kashanian J, Shteynshluyger A, Lee M, Shabsigh R. Erectile dysfunction and testosterone deficiency. Front Horm Res 2009, 37:108-22.
12. Tal R, Valenzuela R, Aviv N, Parker M, Waters WB, Flanigan RC, Mulhall JP. Persistent erectile dysfunction following radical prostatectomy: The association between nerve-sparing status and the prevalence and chronology of venous leak. J Sex Med 2009, 6:2813-9.
13. Zhang LW, Piao S, Choi MJ, Shin HY, Jin HR, Kim WJ, Song SU, Han JY, Park SH, Mamura M, Kim SJ, Ryu JK, Suh JK. Role of increased penile expression of transforming growth factor-beta1 and activation of the Smad signaling pathway in erectile dysfunction in streptozotocin-induced diabetic rats. J Sex Med 2008, 5:2318-29.
14. Ryu JK, Song SU, Choi HK, Seong DH, Yoon SM, Kim SJ, Suh JK. Plasma transforming growth factor-beta1 levels in patients with erectile dysfunction. Asian J Androl 2004, 6:349-53.
15. Cantini LP, Ferrini MG, Vernet D, Magee TR, Quian A, Gelfand RA, Rajfer J, Gonzalez-Cadavid NF. Pro-fibrotic role of myostatin in Peyronie's disease. J Sex Med 2008, 5:1607-22.
16. Gonzalez-Cadavid NF, Rajfer J. Experimental models for Peyronie's disease. Implications for therapy. J Sex Med 2009, 6:303-13.
17. Toblli JE, Ferrini MG, Cao G, Vernet D, Angerosa M, Gonzalez-Cadavid NF. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol Dial Transpl 2009, 24:2384-91.
18. Sarafidis PA, Bakris GL. Protection of the kidney by thiazolidinediones: An assessment from bench to bedside. Kidney Int 2006, 70:1223-33.
19. Ferrini MG, Davila H, Valente EG. Aging-related induction of inducible nitric oxide synthase (iNOS) is vasculo-protective in the arterial media. Cardiovascular Res 2007, 61:796-805. Gonzalez-Cadavid NF*, Rajfer J*, *equal contributors
20. Kovanecz I, Nolazco G, Ferrini MG, Toblli JE, Heydarkhan S, Vernet D, Rajfer J, Gonzalez-Cadavid NF. Early onset of fibrosis within the arterial media in a rat model of type 2 diabetes mellitus exhibiting erectile dysfunction. BJU Int 2009, 103:1396-404.
21. Gonzalez-Cadavid NF, Rajfer J. The pleiotropic effects of inducible nitric oxide synthase on the physiology and pathology of penile erection. Curr Pharm Des 2005, 11:4041-6.
22. Garban H, Marquez D, Magee T, Moody J, Rajavashisht T, Rodriguez JA, Hung A, Vernet D, Rajfer J, Gonzalez-Cadavid NF. Cloning of rat and human inducible penile nitric oxide synthase. Application for gene therapy of erectile dysfunction. Biol Reprod 1997, 56:954-63.
23. Davila HH, Magee TR, Rajfer J, Gonzalez-Cadavid NF. Gene therapy with the inducible nitric oxide synthase (iNOS) cDNA regresses the fibrotic plaque in an animal model of Peyronie's disease. Biol Reprod 2004, 71:1568-77.
24. Ferrini MG, Vernet D, Magee TR, Shahed A, Quian A, Rajfer J, Gonzalez-Cadavid NF. Antifibrotic role of inducible nitric oxide synthase (iNOS). Nitric Oxide 2002, 6:283-94.
25. Vernet D, Ferrini MG, Valente E, Magee TR, Bou-Gharios G, Rajfer J, Gonzalez-Cadavid NF. Effect of nitric oxide on the differentiation of fibroblasts into myofibroblasts in the Peyronie's fibrotic plaque and in its rat model. Nitric Oxide 2002, 7:262-76.
26. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF. L-arginine and PDE inhibitors counteract fibrosis in Peyronie's plaque and related fibroblast cultures. Nitric Oxide 2003, 9:229-44.
27. Hesse M, Cheever AW, Jankovic D, Wynn TA. NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the Th1-inducing adjuvant, IL-12, in a Th2 model of granulomatous disease. Am J Pathol 2000, 157:945-55.
28. Hochberg D, Johnson CW, Chen J, Cohen D, Stern J, Vaughan ED, Poppas D, Felsen D. Interstitial fibrosis of unilateral ureteral obstruction is exacerbated in kidneys of mice lacking the gene for inducible nitric oxide synthase. Lab Invest 2000, 80:1721-8.
29. Trachtman H, Futterweit S, Pine E, Mann J, Valderrama E. Chronic diabetic nephropathy: Role of inducible nitric oxide synthase. Pediatr Nephrol 2002, 17:20-9.
30. Chen Y, Hozawa S, Sawamura S, Sato S, Fukuyama N, Tsuji C, Mine T, Okada Y, Tanino R, Ogushi Y, Nakazawa H. Deficiency of inducible nitric oxide synthase exacerbates hepatic fibrosis in mice fed high-fat diet. Biochem Biophys Res Commun 2005, 326:45-51.
31. Lu L, Chen SS, Hassid A, Sun Y. Cardiac fibrogenesis following infarction in mice with deletion of inducible nitric oxide synthase. Am J Med Sci 2008, 335:431-8.
32. Aram G, Potter JJ, Liu X, Torbenson MS, Mezey E. Lack of inducible nitric oxide synthase leads to increased hepatic apoptosis and decreased fibrosis in mice after chronic carbon tetrachloride administration. Hepatology 2008, 47:2051-8.
33. Zhang P, Xu X, Hu X, van Deel ED, Zhu G, Chen Y. Inducible nitric oxide synthase deficiency protects the heart from systolic overload-induced ventricular hypertrophy and congestive heart failure. Circ Res 2007, 100:1089-98.
34. Zeidler P, Hubbs A, Battelli L, Castranova V. Role of inducible nitric oxide synthase-derived nitric oxide in silica-induced pulmonary inflammation and fibrosis. J Toxicol Environ Health A 2004, 67:1001-26.
35. Bautista-García P, Sánchez-Lozada LG, Cristóbal-García M, Tapia E, Soto V, Avila-Casado MC, Márquez-Velasco R, Bojalil R, Franco M, Herrera-Acosta J. Chronic inhibition of NOS-2 ameliorates renal injury, as well as COX-2 and TGF-beta 1 overexpression in 5/6 nephrectomized rats. Nephrol Dial Transplant 2006, 21:3074-81.
36. Kadkhodaee M, Zahmatkesh M, Sadeghipour HR, Eslamifar A, Taeb J, Shams A, Mahdavi-Mazdeh M. Proteinuria is reduced by inhibition of inducible nitric oxide synthase in rat renal ischemia-reperfusion injury. Transplant Proc 2009, 41:2907-9.
37. Park KM, Byun JY, Kramers C, Kim JI, Huang PL, Bonventre JV. Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney. J Biol Chem 2003, 278:27256-66.
38. Jones SP, Bolli R. The ubiquitous role of nitric oxide in cardioprotection. J Mol Cell Cardiol 2006, 40:16-23.
39. Bayir H, Kagan VE, Borisenko GG, Tyurina YY, Janesko KL, Vagni VA, Billiar TR, Williams DL, Kochanek PM. Enhanced oxidative stress in iNOS deficient mice after traumatic brain injury: Support for a neuroprotective role of iNOS. J Cereb Blood Flow Metab 2005, 25:673-84.
40. Imamura G, Bertelli AA, Bertelli A, Otani H, Maulik N, Das DK. Pharmacological preconditioning with resveratrol: An insight with iNOS knockout mice. Am J Physiol Heart Circ Physiol 2002, 282:H1996-2003.
41. Liu YH, Carretero OA, Cingolani OH, Liao TD, Sun Y, Xu J, Li LY, Pagano PJ, Yang JJ, Yang XP. Role of inducible nitric oxide synthase in cardiac function and remodeling in mice with heart failure due to myocardial infarction. Am J Physiol Heart Circ Physiol 2005, 289:H2616-23.
42. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation 2001, 103:3099-104.
43. Agardh CD, Agardh E, Hultberg B, Ahrén B. Long-standing hyperglycemia in C57BL/6J mice does not affect retinal glutathione levels or endothelial/pericyte ratio in retinal capillaries. J Diabetes Complications 2000, 14:146-53.
44. Flodström M, Tyrberg B, Eizirik DL, Sandler S. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes 1999, 48:706-13.
45. Lu XM, Zhang GX, Yu YQ, Kimura S, Nishiyama A, Matsuyoshi H, Shimizu J, Takaki M. The opposite roles of nNOS in cardiac ischemia-reperfusion-induced injury and in ischemia pre-conditioning-induced cardioprotection in mice. J Physiol Sci 2009, 59:253-62.
46. Ridnour LA, Thomas DD, Donzelli S, Espey MG, Roberts DD, Wink DA, Isenberg JS. The biphasic nature of nitric oxide responses in tumor biology. Antioxid Redox Signal 2006, 8:1329-37.
47. Bachman KE, Park BH. Duel nature of TGF-beta signaling: Tumor suppressor vs. tumor promoter. Curr Opin Oncol 2005, 17:49-54.
48. Ashcroft GS. Bidirectional regulation of macrophage function by TGF-beta. Microbes Infect 1999, 1:1275-82.
49. Ferrini M, Wang C, Swerdloff RS, Sinha Hikim AP, Rajfer J, Gonzalez-Cadavid NF. Aging-related increased expression of inducible nitric oxide synthase and cytotoxicity markers in rat hypothalamic regions associated with male reproductive function. Neuroendocrinology 2001, 74:1-11.
50. Park K, Ryu KS, Li WJ, Kim SW, Paick JS. Chronic treatment with a type 5 phosphodiesterase inhibitor suppresses apoptosis of corporal smooth muscle by potentiating Akt signalling in a rat model of diabetic erectile dysfunction. Eur Urol 2008, 53:1282-8.
51. Xie D, Odronic SI, Wu F, Pippen A, Donatucci CF, Annex BH. Mouse model of erectile dysfunction due to diet-induced diabetes mellitus. Urology 2007, 70:196-201.
52. Bozkurt NB, Pekiner C. Impairment of endothelium- and nerve-mediated relaxation responses in the cavernosal smooth muscle of experimentally diabetic rabbits: Role of weight loss and duration of diabetes. Naunyn Schmiedebergs Arch Pharmacol 2006, 373:71-8.
53. Cartledge JJ, Eardley I, Morrison JF. Nitric oxide-mediated corpus cavernosal smooth muscle relaxation is impaired in ageing and diabetes. BJU Int 2001, 87:394-401.
54. Büyükafşar K, Un I. Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice. Eur J Pharmacol 2003, 472:235-8.
55. Aversa A, Greco E, Bruzziches R, Pili M, Rosano G, Spera G. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: A pilot study. Int J Impot Res 2007, 19:200-7.
56. Musicki B, Burnett AL. Endothelial dysfunction in diabetic erectile dysfunction. Int J Impot Res 2007, 19:129-38.
57. Jones RW, Jeremy JY, Koupparis A, Persad R, Shukla N. Cavernosal dysfunction in a rabbit model of hyperhomocysteinaemia. BJU Int 2005, 95:125-30.
58. Hung A, Vernet D, Xie Y, Rajavashisth T, Rodríguez JA, Rajfer J, González-Cadavid NF. Expression of inducible nitric oxide synthase in smooth muscle cells from rat penile corpora cavernosa. J Androl 1995, 16:469-81.
59. Rajasekaran M, Mondal D, Agrawal K, Chen IL, Hellstrom W, Sikka S. Ex vivo expression of nitric oxide synthase isoforms (eNOS/iNOS) and calmodulin in human penile cavernosal cells. J Urol 1998, 160:2210-5.
60. Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N, Polak J, Wang RZ, Ferguson K, Block C, Haas C. Advanced glycation end products in human penis: Elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997, 50:1016-26.
61. Bivalacqua TJ, Diner EK, Novak TE, Vohra Y, Sikka SC, Champion HC, Kadowitz PJ, Hellstrom WJ. A rat model of Peyronie's disease associated with a decrease in erectile activity and an increase in inducible nitric oxide synthase protein expression. J Urol 2000, 163:1992-8.